

Outcomes of Bentall procedure for prosthetic aortic valve endocarditis with a periannular abscess: a retrospective study

R.M. Samur^a, H. de Beaufort^b, U. Sonker^b,

^a *Faculty of Medicine of Utrecht University*

^b *Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands*

Student number: 6109292

Period of internship: 17-7-2023 to 6-10-2023

Date: 26-9-2023

List of abbreviations

PVE = prosthetic valve endocarditis

AVR = aortic valve replacement

LVOT = left ventricular outflow tract

CRP = C-reactive protein

TTE = Transthoracic Echocardiography

TEE = Transesophageal Echocardiography

CT = Cardiac Computed Tomography

PET = Positron Emission Tomography

CABG = coronary artery bypass grafting

NYHA = New York Heart Association

SD = standard deviation

IQR = Interquartile range

ICU = intensive care unit

Abstract

Background and aims: Prosthetic aortic valve endocarditis (PVE) with aortic root abscess is a lethal condition requiring surgical treatment. The Bentall procedure, involving replacement of aortic valve, aortic root, and ascending aorta is a valuable approach for managing PVE. The objective of this study was to evaluate the clinical outcomes of patients who underwent a re-operation of the aortic root for prosthetic aortic valve endocarditis.

Methods: A retrospective analysis was conducted of all consecutive patients who underwent aortic root replacement surgery for PVE with or without a periannular abscess at Sint Antonius Hospital between February 2011 and August 2022. The primary outcome included in-hospital mortality. Secondary outcomes are follow-up survival rates, postoperative complications.

Results: Thirty-eight patients were included. The in-hospital mortality was 18.4% (n=7) and 5-year survival was 73.7%. The causes of death were various, consisting of heart failure, myocardial infarction, liver failure, hemodynamic shock, and poor neurological outcome leading to treatment discontinuation. Other postoperative complications such as re-intubation for respiratory complications, renal failure requiring dialysis, and permanent neurologic dysfunction were observed in five (13.2%), seven (18.2%) and five (13.2%) patients, respectively. Late complications included re-endocarditis in three patients (7.9%), wound complications in three patients (7.9%), and mitral valve insufficiency in 3 patients (7.9%).

Conclusions: The Bentall reoperation is an effective approach for addressing prosthetic aortic valve endocarditis with root abscess, although it is associated with high postoperative mortality and morbidity rates. However, the 5-year survival outcome remains satisfactory in this context.

Keywords: prosthetic aortic valve endocarditis; Bentall procedure/technique; re-operation; aortic root abscess; aortic valve; postoperative outcomes; mortality; complications; retrospective study

Introduction

Endocarditis, also known as infective endocarditis, is an inner wall inflammation of the heart and heart valves. [1-3] The estimated incidence of endocarditis ranges from 3 to 10 cases per 100,000 people per year.[1] Twenty percent of cases of endocarditis are cases of prosthetic valve endocarditis (PVE). [4-6]

PVE after aortic valve replacement (AVR) is a commonly performed surgery with nearly 1,500 isolated AVR procedures and 800 combined with CABG in 2022 in the Netherlands (*Hart en Vaatcijfers, 2022*) [7]. Furthermore, it is a serious and life-threatening condition. [8-10] The

incidence of PVE after AVR varies in different studies and populations, but it range between 1% and 2% per year in the majority of observational studies. [9,11] Patients with PVE are initially treated with antibiotics for 6 weeks, but occasionally surgical intervention is required to remove the infected tissue and repair or replace the prosthetic valve. [12] According to the European Society of Cardiology guidelines of 2023, surgical intervention is required for example in those patients who exhibit resistant bacteria, have continue positive blood cultures despite treatment, experience vegetation enlargement, or develop an aortic root abscess or fistula. [12]

Prosthetic aortic valve endocarditis or aortic root abscess can be addressed through the Bentall procedure. This procedure is a complex surgical intervention that involves removing the infected tissue, replacing the aortic valve, reconstructing the aortic root, and replacing the ascending aorta with a composite graft. [13,14] The use of mechanical or bioprosthetic valve graft for aortic root replacement was first introduced in 1968 by Bentall and De Bono. [14,15] After improving the technical details, the Bentall procedure has become the standard operation for addressing aortic root conditions. [13,15] A new technique is a combination with left ventricular outflow tract (LVOT) reconstruction which might be considered in cases where the patient has developed complex destructive aortic root and LVOT endocarditis. [16] Re-operation with the Bentall procedure for PVE is associated with high mortality and morbidity rates in available literature. [15,17,18] In prior investigations, the rates of in-hospital mortality have exhibited variations, ranging from approximately 13% to 25%. [17-21] However, due to the relatively infrequent occurrence of reoperation surgery for PVE, most studies are relatively small and heterogeneous. . [6,9,11,15,17-22]

The objective of this study was to evaluate the clinical outcomes of patients who underwent a re-operation of the aortic root for prosthetic aortic valve endocarditis.

Patients and methods

Design

This study is a single center retrospective cohort study in outcome of patients undergoing a Bentall re-operation for prosthetic aortic valve endocarditis with or without aortic root abscess with the primary objective to analyze the in-hospital mortality.

Study population

The study was performed in accordance with our guidelines for human studies and approved by Medical Ethical Committee of the Sint Antonius Hospital and Medical Research Ethics Committees United. Due to its' retrospective nature, the local medical ethical committee waived the need for informed consent. All patients who underwent an aortic root re-operation for prosthetic aortic valve endocarditis or aortic root abscess after previous cardiac surgery between February 2011 and August 2022 at Sint Antonius Hospital, Nieuwegein, the Netherlands, were studied. Patients also undergoing concomitant (cardiac) surgery were included, but patients undergoing only re-AVR without aortic root replacement or LVOT reconstruction were excluded.

Definitions

Prosthetic aortic valve endocarditis or aortic root abscess were considered to be present if there was clinical evidence, as fever, cardiac murmur, septic embolism, positive blood cultures, increased C-reactive protein (CRP), and signs of infection or abscess on imaging. The imaging techniques used to diagnose endocarditis were Transthoracic Echocardiography (TTE), Transesophageal Echocardiography (TEE), Cardiac Computed Tomography (CT), Positron Emission Tomography (PET).

Patient characteristics collected in the data were defined according to European System for Cardiac Operative Risk Evaluation (Euro SCORE) II parameters. [23] Hypertension was scored by using one or more antihypertensive medication and coronary artery disease was scored by presence of percutaneous coronary intervention, coronary artery bypass grafting (CABG) or stenosis >70% with conservative management in past medical history. Furthermore, New York Heart Association (NYHA) Classification was used to define heart failure symptoms. [24] The primary outcome, in-hospital mortality, was defined as death during first hospitalization stay before discharge regardless of hospitalization duration. Secondary outcomes were overall mortality, follow up outcomes and other early major postoperative complications during first hospitalization, including acute myocardial infarction, complete atrioventricular block, stroke, respiratory complications, renal failure, low output state, and re-thoracotomy for operative related complications. Overall mortality was defined as death after hospital discharge.

Surgical technique

All patients were reoperated by median sternotomy. Cardiopulmonary bypass was performed by cannulating ascending aorta, aortic arch, or femoral artery and bicaval cannulation. All procedures were performed on-clamp, with the crossclamp placed in the proximal aortic arch. In most cases, procedures were done under moderate hypothermia (32°C). The infected region was approached by aortotomy incision. After excision of the infected valve and debridement of all necrotic tissue, the size of aortic annulus was measured. Aortic valve and root replacement was constructed by biological or mechanical prosthesis. The selection of the type prosthesis was based on patient characteristics. In patients with annular erosion due to extensive annular abscess and aortic root destruction, LVOT reconstruction was performed with bovine pericardial patch. This patch was used to restore the aortomitral continuity, allowing the positioning of a new valve prosthesis and keeping the function of the mitral valve intact. Associated other surgical procedures such as CABG or MVP were commonly performed prior to the Bentall.

Data collection and statistical analysis

Data was extracted from Electronic Medical Records (EPIC and Metavision) and collected in REDCap® by one investigator, but any issues were discussed with other investigators. Categorical data were presented as number (%). Continuous data were presented as mean ± standard deviation (SD) or median [Interquartile range; IQR]. Survival analysis was performed using SPSS software version 26. The Kaplan-Meier method was used to outline overall mortality.

Pre-operative data included patient characteristics (demographic, comorbidities, clinical presentation), microbiologic data, and imaging details. Operative data included type of explanted and implanted prosthesis, concomitant surgery, operative time, cardiopulmonary

bypass time, cross-clamp time, severity of endocarditis, arterial cannulation, minimum hypothermia, and intra-operative cultures. Postoperative data included mortality, hospital stay duration, major complications, organ failure, neurological dysfunction and late outcomes.

Results

Baseline patient characteristics

We identified 38 patients, comprising 30 males (78.9%) and 8 females (21.1%), with a mean age of 61.5 (\pm 12.6) years (Table 1).

Approximately one-quarter of patients presented with one or more clinical signs of decompensation. Among these, 11 patients (28.9%) displayed peripheral edema, and 4 patients (10.5%) required oxygen support. Not all of these were the same patients, but 11 of the decompensated patients (28.9%) were treated pre-operatively with intravenous diuretics. Notably, none of the included patients had a left ventricular ejection fraction below 30%. Only 8 patients (21.1%) had a moderate reduced ejection fraction within the range of 30-50%, while the majority (n=30; 78.9%) had a preserved ejection fraction exceeding 50%. Moreover, 14 patients (36.8%) were classified as NYHA class one, 13 (34.2%) as NYHA class two, 5 (13.2%) as NYHA class three, and 6 (15.8%) as NYHA class four.

Furthermore, several patients had one or more septic emboli, which complicated by endocarditis during their pre-operative clinical admission. The subsequent data on these septic emboli have been collected: 3 patients (7.9%) experienced renal infarction, 4 patients (10.5%) exhibited splenic infarction and 8 patients (21.1%) suffered from embolic stroke.

Regarding temperature ($^{\circ}$ C) and CRP data, the highest values during the current hospitalization were recorded. The median temperature was 38.4 $^{\circ}$ C [37.8-39.0] and the median CRP level was 207 [106-273].

In terms of the timing of surgery, all patients presented with an urgent surgical indication (n=37; 97.4%) except one patient who was classified as emergent (2.6%) and required immediate intervention due to the presence of a vegetation exceeding 2 centimeters in size. Urgent operation was defined as surgery within the same hospital admission. Furthermore, the preoperative surgical risk was assessed using EuroSCORE II, yielding a median score of 16.6 [11.6-39.4].

The clinical preoperative electrocardiograms demonstrated sinus rhythm in 16 patients (42.1%), supraventricular tachycardia in 9 patients (23.7%), right or left bundle branch block in 2 patients (5.3%), first-degree atrioventricular block in 3 patients (7.9%), second-degree atrioventricular block in 1 patient (2.6%), and total atrioventricular block in 7 patients (18.4%). Among the patients with atrioventricular block, 5 (13.2%) had an internal pacemaker in place prior to aortic root replacement, while the remaining two cases were new occurrences possibly related to the endocarditis. One patient received a permanent

pacemaker postoperatively, whereas the other patient did not survive the postoperative period.

Ultimately, all patients had previously undergone aortic valve surgery, with several having also undergone additional cardiac or thoracic surgical procedures. Of the total cohort, 19 patients (50%) had a surgical history of AVR, and an equal number, 19 (50%), had a surgical history of a Bentall procedure. Additionally, 11 patients (28.9%) had undergone supracoronary ascending or arch replacement, 2 patients (5.3%) had undergone valvulotomy, and the remaining 3 patients (7.9%) had undergone various other thoracic surgeries, including a Ross procedure, segmental lung resection, and ventricular septal defect patch closure.

Table 1: Baseline patient characteristics (n=38)

Variable	Result
	N (%), mean \pm SD (range) or median [IQR]
Age (y)	61.5 \pm 12.6
Male	30 (78.9)
Comorbidities	
Hypertension	19 (50.0)
Smoking	8 (21.1)
IDDM	3 (7.9)
Obesity (BMI \geq 30)	6 (15.8)
Chronic pulmonary disease	6 (15.8)
PAD	4 (10.5)
CAD	14 (36.8)
Renal insufficiency (GFR <50 ml/min)	9 (23.7)
Stroke or TIA	10 (26.3)
Clinical presentation	
Signs of decompensation	
Nasal cannula oxygen support	4 (10.5)
Intravenous diuretics	11 (28.9)
Peripheral edema	11 (28.9)
Pre-operative LVEF (%)	
30-50%	8 (21.1)
>50%	30 (78.9)
NYHA	
I	14 (36.8)
II	13 (34.2)
III	5 (13.2)
IV	6 (15.8)
Septic embolism	
Renal infarction	3 (7.9)
Splenic infarction	4 (10.5)
Stroke or TIA	8 (21.1)
Temperature ($^{\circ}$ C)	38.4 [37.8-39.0]
CRP (mg/l)	207 [106-273]
Timing of surgery	
Urgent	37 (97.4)
Emergency	1 (2.6)
Euro SCORE II (%)	16.6 [11.6-39.4]
Pre-operative electrocardiogram	
Sinus rhythm	16 (42.1)
(Paroxysmal) atrial fibrillation or flutter	9 (23.7)
Right/left bundle branch block	2 (5.3)

1 st degree AV-block	3 (7.9)
2 nd degree AV-block	1 (2.6)
Total AV-block	7 (18.4)
Internal pacemaker	5 (13.2)
Previous thoracic surgery	
CABG	12 (31.6)
AVR	19 (50.0)
Valvulotomy	2 (5.3)
Bentall	19 (50.0)
Supracoronary ascending or arch replacement	11 (28.9)
Other*	3 (7.9)

Data shown are numbers of cases (%), mean \pm standard deviation, and median [interquartile range]. IDDM, insulin dependent diabetes mellitus; PAD, peripheral artery disease; CAD, coronary artery disease; GFR, glomerular filtration rate; TIA, transient ischemic attack; LVEF, left ventricle ejection fraction; NYHA, New York Heart Association; CRP, C-reactive protein; AV, atrioventricular; CABG, coronary artery bypass grafting; AVR, aortic valve replacement.

*Other: Ross switch, ventricular septal defect closure and segmental lung resection

Bacterial origins of endocarditis

Table 2 presents the causative microbes of prosthetic aortic valve endocarditis.

Staphylococcus aureus was the most prevalent organism, detected in 14 cases (36.8%). Streptococci were the subsequent most common species, appearing in 8 cases (21.1%). Enterococci were identified in 6 cases (15.8%), and *Propionibacterium acnes* in 3 cases (7.9%). In one instance (2.6%), the culture yielded no growth.

Additionally, the median duration of antibiotic use before the surgery was 16 [8-26] days. In relation to this, two patients had not received pre-operative antibiotic management. In the first case, endocarditis was not suspected; however, the operation was indicated due to anastomotic leakage after a Bentall operation. In the second case, the patient had been managed with long-term antibiotics a year prior. Following aortic root abscess and clinical deterioration one year later, the patient underwent a Bentall reoperation.

Table 2: Microbiologic data (n=38)

Variable	Result
	N (%) or median [IQR]
Microorganism	
Enterococcus faecium/faecalis	6 (15.8)
Propionibacterium acnes	3 (7.9)
Staphylococcus aureus	14 (36.8)
Streptococcus species	8 (21.1)
Other	6 (15.8)
Culture negative	1 (2.6)
Antibiotic use before the surgery	36 (94.7)
Duration of antibiotic use before the surgery (days)	16 [8-26]

Data shown are numbers of cases (%), and median [interquartile range].

Imaging

The outcomes arising from imaging examinations utilized for the diagnostic assessment of endocarditis are illustrated in Table 3. Initially, TTE was conducted in 34 patients. Within the complete sample, 47.1% (n=16) exhibited neither vegetations nor abscess. Vegetations were detected in 32.4% (n=11) of the cases, while 35.3% (n=12) demonstrated aortic abscess or thickening around the prosthesis. TEE was conducted in 35 patients. Absence of both vegetations and abscesses was observed in 5.7% (n=2) of cases, whereas vegetation was

detected in 57.1% (n=20) of cases. Additionally, aortic abscesses or thickening around the prosthesis were identified in 88.6% (n=31) of cases.

Cardiac CT scans and PET-CT scans were undertaken less frequently (in 23 and 22 patients, respectively). In 26.1% of patients (n=6), CT scans exhibited no indications of infection or abscess formation, whereas all PET scans indicated evidence of endocarditis. On the CT scans, aortic abscess were visualized in 47.8% (n=11) of patients, and signs of infection along the aortic wall were observed in 34.8% (n=8) of patients. Conversely, PET scans demonstrated an increased uptake adjacent to the prosthesis in 100% (n=22) of patients who underwent PET imaging. Furthermore, abscesses in aortic root were reported in 2 patients (9.1%) as supplementary findings.

Table 3: Imaging

Variable	Result
	N (%)
TTE	34 (100)
No vegetations, no abscess	16 (47.1)
Vegetations	11 (32.4)
1-2cm	1 (2.9)
Not described	10 (29.4)
Aortic (root) abscess/ thickening around prosthesis	12 (35.3)
Aortic aneurysm	3 (8.8)
Aortic valve stenosis	5 (14.7)
Moderate (PG mean 20-40mmHg; PG max 40-70mmHg)	3 (8.8)
Severe (PG mean >40mmHg; PG max >70mmHg)	2 (5.9)
Aortic valve insufficiency	2 (5.9)
Moderate (grade 3)	1 (2.9)
Severe (grade 4)	1 (2.9)
Mitral valve insufficiency	2 (5.9)
Moderate (grade 3)	1 (2.9)
Severe (grade 4)	1 (2.9)
TEE	35 (100)
No vegetations, no abscess	2 (5.7)
Vegetations	20 (57.1)
<1cm	2 (5.7)
1-2cm	5 (14.3)
>2cm	1 (2.9)
Not described	12 (34.3)
Aortic (root) abscess/ thickening around prosthesis	31 (88.6)
Aortic aneurysm	5 (14.3)
Aortic valve insufficiency	2 (5.7)
Severe (grade 4)	2 (5.7)
Mitral valve insufficiency	4 (11.4)
Moderate (grade 3)	4 (11.4)
Flow between left atrium and aorta suggestive for perforation	1 (2.9)
CT-Heart/Aorta	23 (100)
No signs of infection or abscess	6 (26.1)
Mediastinal fluid collection	7 (30.4)
Aortic (root) abscess	11 (47.8)
Thickened aortic wall/ wall contrast uptake	8 (34.8)
Aortic aneurysm	8 (34.8)
Enlarged mediastinal lymph nodes	3 (13.0)
PET	22 (100)
No signs of infection or abscess	0 (0.0)

Increased uptake of prosthesis suggestive for infection	22 (100)
Aortic (root) abscess	2 (9.1)
Reactive mediastinal lymph nodes	10 (45.5)
Increased uptake in joints/bones (e.g. spondylodiscitis)	5 (22.7)
Increased uptake in soft tissue (e.g. vasculitis)	8 (36.4)

Data shown are numbers of cases (%). TTE, transthoracic echocardiogram; cm, centimeters; PG, pressure gradient; TEE, transesophageal echocardiogram; CT, computed tomography; PET, Positron Emission Tomography.

Operative details

Table 4 summarize the operative surgical details. At the time of the reoperation, 24 patients (63.2%) received a biological prosthesis, while 13 patients (34.2%) received a mechanical prosthesis. Concomitant surgeries included LVOT reconstruction using a pericardial patch in 33 patients (86.8%), mitral valve repair in 10 patients (26.3%), mitral valve replacement in one patient (2.6%), CABG in 3 patients (7.9%), and pacemaker lead extraction in 4 patients (10.5%). Partial aortic arch replacement was executed in one patient (2.6%) due to an aneurysm. Ultimately, a laparotomy during the surgery was undertaken in another patient (2.6%) owing to perioperative retroperitoneal bleeding as a consequence of iatrogenic injury by advancing a guidewire.

The median operative, cardiopulmonary bypass, and aortic cross-clamp times were 492 [427-627] minutes, 312 [275-395] minutes, and 217 [188-250] minutes, respectively. Deep hypothermic circulatory arrest was utilized in 2 patients (5.3%), the one lasting 30 minutes with a minimum temperature of 20.0°C due to ascending aorta replacement, and the other enduring for 71 minutes with a minimum temperature of 24.2°C due to aortic arch replacement.

After all, half of the intraoperatively obtained cultures (n=15; 39.5%) yielded positive results, although the other half yielded negative results.

Table 4: Operative data (n=38)

Variable	Result
	N (%), mean ± SD (range) or median [IQR]
Type of explanted prosthesis	
Biological aortic valve	7 (18.4)
Mechanical aortic valve	12 (31.6)
Biological Bentall	7 (18.4)
Mechanical Bentall	12 (31.6)
Implanted prosthesis	
Name and type	
Biological prosthesis*	24 (63.2)
Mechanical prosthesis**	13 (34.2)
Unknown	1 (2.6)
Diameter of aortic valve prosthesis (mm)	24.5 ± 1.4
Diameter of aortic root prosthesis (mm)	26.7 ± 2.7
Concomitant surgery	
No concomitant surgery	23 (60.5)
Pericardial patch	33 (86.8)
MVP	10 (26.3)
MVR	1 (2.6)
CABG	3 (7.9)
Partial aortic arch replacement	1 (2.6)

Ascending aorta replacement	1 (2.6)
Lead extraction	4 (10.5)
Laparotomy by perioperative complication	1 (2.6)
Operative time (min)	492 [427-627]
Missing data	16 (42.1)
Cardiopulmonary bypass time (min)	312 [275-395]
Missing data	2 (5.3)
Cross-clamp time (min)	217 [188-250]
Missing data	2 (5.3)
Arterial cannulation	
Ascending aorta	14 (36.8)
Arch of aorta	11 (28.9)
Femoral artery	10 (26.3)
Missing data	3 (7.9)
Minimum hypothermia (°C)	29.5 [28.0-31.3]
Missing data	1 (2.6)
Deep hypothermic circulatory arrest (n)	2 (5.3)
Intraoperative cultures	
Positive	15 (39.5)
Negative	15 (39.5)
Not performed/no information	8 (21.1)

Data shown are numbers of cases (%), mean \pm standard deviation, and median [interquartile range]. MVP, mitral valve plasty; MVR, mitral valve replacement; CABG, coronary artery bypass grafting; mm, millimeters.

*Biological prosthesis: Mitroflow Crown PRT, Mitroflow Valsalva Conduit, Perimount Magna Ease, Medtronic Freestyle, INSPIRIS Resilia

*Mechanical prosthesis: Carbomedics Carbo-Seal

Postoperative clinical outcomes

Early postoperative outcomes are outlined in [Table 5](#). No patient died during the operation, but certain patients had a complicated postoperative course. In-hospital mortality occurred in 7 patients (18.4%). The reasons for death were pneumosepsis, myocardial infarction, septic shock, right ventricle failure, liver failure, hemodynamic instability with recurrent tamponades, and severe neurological injury due to perioperative stroke. The median intensive care unit (ICU) stay was 4 [2-12] days, and hospital stay was 18 [12-32] days. Nevertheless, 44.7% of these patients (n=17) were transferred to another hospital or nursing home for further healing and rehabilitation.

Among the 2 patients (5.3%) who experienced postoperative acute myocardial infarctions, one of them died to the condition. This patient manifested anterior wall infarction given that adhesive material entered the coronary artery during the surgery, which was subsequently aspirated with the expectation that it would not pose a problem. However, postoperatively, elevated cardiac enzyme levels and akinesia of the anterior wall were observed, necessitating coronary angiography. Subsequent assessment revealed sufficient blood flow. Consequently, the patient was managed with high-dose inotropes and ECMO support for cardiac assistance. Despite these interventions, minimal progress was achieved, leading to the unfortunate demise of the patient. The other patient also had increased cardiac enzyme levels postoperatively, necessitating coronary angiography. Subsequently, no coronary artery disease was evident, except for an occlusion of the posterolateral branch, attributed to (septic) embolism originating from the vegetation associated with endocarditis, resulting in papillary muscle infarction and subsequently mitral valve insufficiency. As a solution, a re-operation for mitral valve replacement was performed.

In total, nine patients underwent rethoracotomy during same admission for early complications, which included bleeding/tamponade in 6 patients (15.8%), shock/arrest in 2 patients (5.3%), mediastinitis in 2 patients (5.3%), and valvular complication in 1 patient (2.6%). The valvular complication was a mitral valve insufficiency, for which the patient underwent a re-operation for mitral valve replacement. Furthermore, a number of patients encountered a postoperative low output state. Six patient (15.8%) received extracorporeal membrane oxygenation support and 13 (34.2%) were dependent on inotropy/vasopression for more than 48 hours.

In addition, renal failure needing dialysis occurred in 7 patients (18.4%), and re-intubation due to respiratory complications occurred in 5 patients (13.2%), due to pneumonia, decompensation, septic episode with prolonged mechanical ventilation, pulmonary emphysema with recurrent pneumonia, and ICU acquired weakness with sputum. Other complications included complete atrioventricular block with permanent pacemaker implantation in 7 patients (18.4%), transient neurologic dysfunction in 1 patient (2.6%), and permanent neurologic dysfunction in 5 patients (13.2%), resulting in death in one patient.

Table 5: Postoperative outcomes (n=38)

Variable	Result
	N (%) or median [IQR]
In-hospital mortality	7 (18.4)
ICU stay (days)	4 [2-12]
Hospital stay (days)	18 [12-32]
Acute myocardial infarction	2 (5.3)
Atrial fibrillation new onset	6 (15.8)
New permanent pacemaker implantation	7 (18.4)
Rethoracotomy for early complications	
Bleeding/tamponade	6 (15.8)
Shock/arrest	2 (5.3)
Mediatinitis	2 (5.3)
Valvular complication	1 (2.6)
Low output state	
ECMO	6 (15.8)
>48 hours inotropy or vasopression dependent	13 (34.2)
Renal failure	7 (18.4)
Respiratory complications needing reintubation	5 (13.2)
Transient neurologic dysfunction	1 (2.6)
Permanent neurologic dysfunction	5 (13.2)
Postoperative echocardiogram: MI	2 (5.3)


Data shown are numbers of cases (%), and median [interquartile range]. ICU= Intensive Care Unit, ECMO= extracorporeal membrane oxygenation, MI= mitral valve insufficiency

Long-term follow up outcomes

During follow up, three more patients did not survive; one of these deaths was caused by re-endocarditis. In contrast , the other two deaths were caused by non-cardiac conditions (liver failure and lung carcinoma). Two mortalities occurred one year later and one mortality occurred approximately five years later, resulting in no mortalities after the initial 5-year period. The overall Kaplan Meier estimated survival rate at 5 years was 73.7% (Fig. 1). However, there are patients who have undergone surgery much more recently, and therefore, they have not been followed for an extended duration.

Other late outcome complications included re-endocarditis in 3 patients (7.9%), wound complication requiring re-intervention in 3 patients (7.9%), and pseudo aneurysm requiring re-intervention in 3 patients (7.9%). Furthermore, 4 patients (10.5%) developed heart failure with NYHA ≥ 2 , and 1 patients (2.6%) experienced mitral valve insufficiency who underwent mitral valve repair.

Figure 1: Kaplan-Meier curve for overall survival



Time	0	2	4	6	8	10
No. of patient at risk	38	16	9	5	1	0

Discussion

This study aimed to evaluate the clinical outcomes and long-term results of reoperations for prosthetic aortic valve endocarditis or aortic root abscess. Surgical intervention is typically indicated in these circumstances, although it is associated with high in-hospital mortality rate (18.4%) and postoperative complications. The 5-year survival rate of 73.7% suggests relatively favorable long-term outcomes, considering the complexity of the cases. These findings are reasonably consistent with other publications. Sponga et al. examined 73 patients with Bentall procedure related endocarditis, reporting a 30-day mortality rate of 15% and a 5-year survival rate of 75%. [17] Cefarelli et al. studied 29 patients who undergone a biological Bentall reoperation for aortic valve endocarditis with root abscess. [18] They described a 30-day mortality rate of 13.8% and a 5-year survival rate of 75.6%. [19] Other studies in the literature also report comparable outcomes. However, these outcomes stem from various reoperation techniques, rendering direct comparisons somewhat challenging.

Moreover, the most studies in the literature have explored PVE without patients presenting an aortic root abscess.

In contrast to prior investigation, the prevalent approach in our study cohort involved employing bovine pericardial patches for LVOT reconstruction due to destruction of the aortic annulus caused by paravalvular abscess. The literature describes that LVOT reconstruction is essential for an effective treatment of complex aortic valve endocarditis with paravalvular abscess. [25-28] Regarding the duration of surgical details, operative times were relatively long compared to the previous studies, with long cardiopulmonary bypass time, and cross-clamp time. This may also be attributed to the LVOT reconstruction technique that we predominantly employed in most cases, but the prolonged time complicate the surgical procedure. Several investigations established that prolonged cardiopulmonary bypass time and cross-clamp are associated with an increased risk of postoperative mortality and morbidity. [29-31] From the study by Nissinen et al., it was observed that cardiac procedures with a perfusion time of <240 minutes and a clamp time of <150 minutes are associated with a lower risk of postoperative complications, independently the complexity of the surgical risk. Prolonged durations could potentially contribute our postoperative mortality outcomes.

Interestingly, none of the patients had a left ventricular ejection fraction below 30%, and a limited number belong to NYHA classes III and IV, which is most likely due to patient selection; with patients having a poor left ventricular function turned down for surgery due to the operative risk. In addition, EuroSCORE II was utilized to estimate the risk of postoperative mortality; however it has not validated for this type of surgery. Nonetheless, the preoperative mortality predictions generally aligned with the actual mortality. In conclusion, the EuroSCORE II can provide some estimation of which patients may experience mortality, but approximately half of the patients with exceptionally high scores survived the procedure. Therefore, it cannot be asserted that surgery is futile for patients with a high EuroSCORE II. Furthermore, the outcomes also exhibited that all patients with a very high EuroSCORE II who received ECMO ultimately died. As a result, the efficacy of ECMO treatment may be questionable.

The predominance of *Staphylococcus aureus* as the causative microbe is noteworthy. Leontyev et al. describe that Staphylococcus infection to be an independent prognostic factor for mortality in patients with abscess formation, and report that Staphylococcus infection is associated with a higher incidence of root abscesses compared to non-Staphylococcal infections. [9]

Multiple imaging techniques are followed to diagnose endocarditis. Imaging modalities disclosed signs of infection or abscess in each patient. TTE and TEE were the most commonly utilized diagnostic imaging modality. Our research revealed that the optimal visualization of the aortic root abscess is achieved through TEE. Furthermore, both CT scans and PET scans were employed to assess the extent of infection. Nevertheless, PET scanning emerged as the most sensitive method for the detection of prosthetic aortic valve endocarditis. The systematic review by Machelart et al. describes high sensitivity and specificity of PET scans for diagnosing PVE, ranging between 70% and 93% and between 91% and 93%, respectively. [32] This is also comparable with the outcomes of our study. All by all, for diagnosing aortic

valve prosthesis endocarditis or aortic root abscess, a combination of imaging modalities including TTE, TEE, CT, and PET is required, with CT being useful for detecting paravalvular disease that may not be diagnosed through echocardiography.

Limitations

The study has several limitations. Firstly, it is a retrospective, non-randomized cohort design, leading to both selection bias and information bias. Secondly, its single-center nature entails a restricted study population with the possibility of referral bias. Additionally, this highly selected group of patients and the small single-center study population render the findings challenging to generalize.

Conclusion

In conclusion, this study shows that the mortality rate for patients undergoing reoperation for prosthetic aortic valve endocarditis is 18.4%. Despite the early high mortality rate, the long-term survival rates are satisfactory, with a low incidence of recurrent endocarditis.

References

1. Yallowitz AW, Decker LC. Infectious Endocarditis. 2023 Apr 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. PMID: 32491573.
2. Vilcant V, Hai O. Bacterial Endocarditis. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. PMID: 29262218.
3. Gupta A, Mendez MD. Endocarditis. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29763019.
4. Khalil H, Soufi S. Prosthetic Valve Endocarditis. 2022 Dec 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. PMID: 33620808.
5. UpToDate. Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis. [Internet] Available from: <https://www.uptodate.com/contents/prosthetic-valve-endocarditis-epidemiology-clinical-manifestations-and-diagnosis#H1> [Accessed 22nd August 2023]
6. Kim YW, Jung SH, Choo SJ, Chung CH, Lee JW, Kim JB. Outcomes of Reoperative Valve Replacement in Patients with Prosthetic Valve Endocarditis: A 20-Year Experience. Korean J Thorac Cardiovasc Surg. 2018 Feb;51(1):15-21. doi: 10.5090/kjtcs.2018.51.1.15. Epub 2018 Feb 5. PMID: 29430424; PMCID: PMC5796613.
7. Hart en vaat cijfers. Jaarcijfers aortakleplijden. [Internet] Available from: <https://www.hartenvaatcijfers.nl/jaarcijfers/jaarcijfers-aortakleplijden-91312> [Accessed 18th September 2023]
8. Leontyev S, Borger MA, Modi P, Lehmann S, Seeburger J, Walther T, et al. Redo aortic valve surgery: Influence of prosthetic valve endocarditis on outcomes. J Thorac

Cardiovasc Surg. 2011 Jul;142(1):99-105. doi: 10.1016/j.jtcvs.2010.08.042. Epub 2010 Oct 15. PMID: 20951390.

9. Jena N, Patel K, Desai R, Siddiqui N, Ahluwalia G, Halabi AR, et al. Surgical Aortic Valve Replacement to Treat Prosthetic Valve Endocarditis After Valve-in-Valve Transcatheter Aortic Valve Replacement. *Cureus*. 2023 Apr 23;15(4):e38021. doi: 10.7759/cureus.38021. PMID: 37228546; PMCID: PMC10205151.
10. Sasaki Y, Isobe F, Kinugasa S, Iwata K, Nagamachi K, Kato Y, et al. Early and late outcomes after reoperation for prosthetic valve endocarditis. *Jpn J Thorac Cardiovasc Surg*. 2001 Apr;49(4):224-9. doi: 10.1007/BF02913520. PMID: 11355255.
11. Lanz J, Reardon MJ, Pilgrim T, Stortecky S, Deeb GM, Chetcuti S, et al. Incidence and Outcomes of Infective Endocarditis After Transcatheter or Surgical Aortic Valve Replacement. *J Am Heart Assoc*. 2021 Oct 5;10(19):e020368. doi: 10.1161/JAHA.120.020368. Epub 2021 Sep 28. PMID: 34581194; PMCID: PMC8649131.
12. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J*. 2015 Nov 21;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319. Epub 2015 Aug 29. PMID: 26320109.
13. Mookhoek A, Korteland NM, Arabkhani B, Di Centa I, Lansac E, Bekkers JA, et al. Bentall Procedure: A Systematic Review and Meta-Analysis. *Ann Thorac Surg*. 2016 May;101(5):1684-9. doi: 10.1016/j.athoracsur.2015.10.090. Epub 2016 Feb 6. PMID: 26857635.
14. Deng J, Zhong Q. Clinical analysis of redo aortic root replacement after cardiac surgery: a retrospective study. *J Cardiothorac Surg*. 2021 Jul 28;16(1):202. doi: 10.1186/s13019-021-01587-8. PMID: 34321011; PMCID: PMC8316709.
15. Mazine A, David TE, Lafreniere-Roula M, Feindel CM, Ouzounian M. Early outcomes of the Bentall procedure after previous cardiac surgery. *J Thorac Cardiovasc Surg*. 2021 Oct;162(4):1063-1071. doi: 10.1016/j.jtcvs.2019.12.134. Epub 2020 Mar 25. PMID: 32387157.
16. Kirali K, Sarikaya S, Ozen Y, Sacli H, Basaran E, Yerlikhan OA, et al. Surgery for Aortic Root Abscess: A 15-Year Experience. *Tex Heart Inst J*. 2016 Feb 1;43(1):20-8. doi: 10.14503/THIJ-14-4747. PMID: 27047281; PMCID: PMC4810580.
17. Sponga S, Di Mauro M, Malvindi PG, Paparella D, Murana G, Pacini D, et al. Surgery for Bentall endocarditis: short- and midterm outcomes from a multicentre registry. *Eur J Cardiothorac Surg*. 2020 Oct 1;58(4):839-846. doi: 10.1093/ejcts/ezaa136. PMID: 32417897

18. Cefarelli M, Concistrè G, Montecchiani L, Bianchi G, Berretta P, Margaryan R, Alfonsi J, Murzi M, Solinas M, Di Eusanio M. Bioconduit subannular implantation for aortic root endocarditis after previous cardiac surgery: Results from two Italian centers. *J Card Surg.* 2020 Nov;35(11):3041-3047. doi: 10.1111/jocs.14970. Epub 2020 Aug 21. PMID: 32827184.
19. Wilbring M, Tugtekin SM, Alexiou K, Matschke K, Kappert U. Composite aortic root replacement for complex prosthetic valve endocarditis: initial clinical results and long-term follow-up of high-risk patients. *Ann Thorac Surg.* 2012 Dec;94(6):1967-74. doi: 10.1016/j.athoracsur.2012.06.027. Epub 2012 Aug 29. PMID: 22939247.
20. Hagl C, Galla JD, Lansman SL, Fink D, Bodian CA, Spielvogel D, Griep RB. Replacing the ascending aorta and aortic valve for acute prosthetic valve endocarditis: is using prosthetic material contraindicated? *Ann Thorac Surg.* 2002 Nov;74(5):S1781-5; discussion S1792-9. doi: 10.1016/s0003-4975(02)04142-5. PMID: 12440665.
21. Musci M, Weng Y, Hübler M, Amiri A, Pasic M, Kosky S, Stein J, Siniawski H, Hetzer R. Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. *J Thorac Cardiovasc Surg.* 2010 Mar;139(3):665-73. doi: 10.1016/j.jtcvs.2009.07.026. Epub 2009 Sep 19. PMID: 19767017.
22. Malvindi PG, Olevano C, Luthra S, Tsang G, Barlow C, Ohri S. Outcomes of patients with acute prosthetic aortic valve endocarditis. *Asian Cardiovasc Thorac Ann.* 2021 May;29(4):268-277. doi: 10.1177/0218492320974112. Epub 2020 Nov 9. PMID: 33167670.
23. EuroSCORE. EuroSCORE II Calculator. [Internet] Available from: <https://www.euroscore.org/index.php?id=17> [Accessed on 3rd September 2023]
24. American Heart Association. Classes and Stages of Heart Failure. Available from: <https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure> [Accessed on 3rd September 2023]
25. Bozbuga N, Erentug V, Erdogan HB, Kirali K, Ardal H, Tas S, Akinci E, Yakut C. Surgical treatment of aortic abscess and fistula. *Tex Heart Inst J.* 2004;31(4):382-6. PMID: 15745289; PMCID: PMC548238.
26. Gomes A, Jainandunsing JS, van Assen S, van Geel PP, Sinha B, Gelsomino S, Johnson DM, Natour E. A standardized approach to treat complex aortic valve endocarditis: a case series. *J Cardiothorac Surg.* 2018 Apr 19;13(1):32. doi: 10.1186/s13019-018-0715-8. PMID: 29673380; PMCID: PMC5909265.
27. El-Sayed Ahmad A, Salamate S, Amer M, Abdullaahi A, Bayram A, Sirat S, et al. Modification of reconstruction of left ventricular outflow tract, aortic root and the intervalvular fibrous body for extensive infective endocarditis: a single-centre experience. *Eur J Cardiothorac Surg.* 2022 Jul 11;62(2):ezac311. doi: 10.1093/ejcts/ezac311. PMID: 35587170.

28. Stamou SC, Murphy MC, Kouchoukos NT. Left ventricular outflow tract reconstruction and translocation of the aortic valve for annular erosion: early and midterm outcomes. *J Thorac Cardiovasc Surg.* 2011 Aug;142(2):292-7. doi: 10.1016/j.jtcvs.2010.09.054. Epub 2010 Dec 3. PMID: 21130469.
29. Salsano A, Giacobbe DR, Sportelli E, Olivieri GM, Natali R, Prevosto M, Del Bono V, Viscoli C, Santini F. Aortic cross-clamp time and cardiopulmonary bypass time: prognostic implications in patients operated on for infective endocarditis. *Interact Cardiovasc Thorac Surg.* 2018 Sep 1;27(3):328-335. doi: 10.1093/icvts/ivy085. PMID: 29579243.
30. Nissinen J, Biancari F, Wistbacka JO, Peltola T, Loponen P, Tarkiainen P, Virkkilä M, Tarkka M. Safe time limits of aortic cross-clamping and cardiopulmonary bypass in adult cardiac surgery. *Perfusion.* 2009 Sep;24(5):297-305. doi: 10.1177/0267659109354656. Epub 2009 Dec 10. PMID: 20007817.
31. Al-Sarraf N, Thalib L, Hughes A, Houlihan M, Tolan M, Young V, McGovern E. Cross-clamp time is an independent predictor of mortality and morbidity in low- and high-risk cardiac patients. *Int J Surg.* 2011;9(1):104-9. doi: 10.1016/j.ijsu.2010.10.007. Epub 2010 Oct 20. PMID: 20965288.
32. Machelart I, Greib C, Wirth G, Camou F, Issa N, Viillard JF, Pellegrin JL, Lazaro E. Graft infection after a Bentall procedure: A case series and systematic review of the literature. *Diagn Microbiol Infect Dis.* 2017 Jun;88(2):158-162. doi: 10.1016/j.diagmicrobio.2017.03.002. Epub 2017 Mar 7. PMID: 28330738.